• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection].[阿那白滞素在治疗新型冠状病毒严重呼吸道感染中的应用]
Reumatol Clin. 2023 Feb;19(2):121. doi: 10.1016/j.reuma.2022.02.003. Epub 2022 Mar 14.
2
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab.阿那白滞素作为治疗对托珠单抗难治的新型冠状病毒肺炎相关严重急性呼吸道感染的潜在替代药物。
Reumatol Clin (Engl Ed). 2020 Jun 17;17(10):559-61. doi: 10.1016/j.reuma.2020.06.003.
3
An open label trial of anakinra to prevent respiratory failure in COVID-19.阿那白滞素预防 COVID-19 呼吸衰竭的开放标签试验。
Elife. 2021 Mar 8;10:e66125. doi: 10.7554/eLife.66125.
4
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab.阿那白滞素作为治疗对托珠单抗难治的 SARS-CoV-2 相关严重急性呼吸道感染的一种潜在替代药物。
Reumatol Clin (Engl Ed). 2021 Dec;17(10):559-561. doi: 10.1016/j.reumae.2020.06.008. Epub 2020 Oct 15.
5
Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis.阿那白滞素治疗 COVID-19 患者：系统评价和荟萃分析。
Eur J Med Res. 2023 Feb 25;28(1):100. doi: 10.1186/s40001-023-01072-z.
6
Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids.两名感染严重急性呼吸综合征冠状病毒2的青少年出现高炎症反应，使用白细胞介素-1抑制剂阿那白滞素和糖皮质激素治疗成功。
Front Pediatr. 2020 Nov 30;8:576912. doi: 10.3389/fped.2020.576912. eCollection 2020.
7
Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study.312 例 SARS-CoV-2 所致中重度肺炎伴高炎症患者应用阿那白滞素和皮质类固醇治疗的特征和临床转归：一项回顾性队列研究。
PLoS One. 2023 Mar 24;18(3):e0283529. doi: 10.1371/journal.pone.0283529. eCollection 2023.
8
Tocilizumab versus anakinra in COVID-19: results from propensity score matching.托珠单抗与阿那白滞素治疗 COVID-19 的疗效比较：倾向评分匹配分析结果。
Front Immunol. 2023 May 26;14:1185716. doi: 10.3389/fimmu.2023.1185716. eCollection 2023.
9
Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection.阿那白滞素在治疗新型冠状病毒严重呼吸道感染中的应用。
Reumatol Clin (Engl Ed). 2023 Feb;19(2):121. doi: 10.1016/j.reumae.2022.02.001. Epub 2022 Jun 24.
10
Anakinra as a potential treatment for COVID-19.
Drugs Today (Barc). 2023 Mar;59(3):107-112. doi: 10.1358/dot.2023.59.3.3542446.

本文引用的文献

1
[Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: coment].[阿那白滞素作为托珠单抗难治的新型冠状病毒肺炎相关严重急性呼吸道感染治疗的潜在替代药物：评论]
Reumatol Clin. 2023 Feb;19(2):120-121. doi: 10.1016/j.reuma.2022.01.003. Epub 2022 Feb 10.
2
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab.阿那白滞素作为治疗对托珠单抗难治的 SARS-CoV-2 相关严重急性呼吸道感染的一种潜在替代药物。
Reumatol Clin (Engl Ed). 2021 Dec;17(10):559-561. doi: 10.1016/j.reumae.2020.06.008. Epub 2020 Oct 15.
3
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.早期使用依那西普联合可溶性尿激酶型纤溶酶原激活物受体血浆水平指导 COVID-19 治疗：一项双盲、随机对照 3 期试验。
Nat Med. 2021 Oct;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z. Epub 2021 Sep 3.
4
An open label trial of anakinra to prevent respiratory failure in COVID-19.阿那白滞素预防 COVID-19 呼吸衰竭的开放标签试验。
Elife. 2021 Mar 8;10:e66125. doi: 10.7554/eLife.66125.
5
Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.COVID-19 治疗药物阿那白滞素、司妥昔单抗、西妥昔单抗和托珠单抗的系统评价和荟萃分析。
Thorax. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12.
6
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.阿那白滞素治疗单独使用皮质类固醇激素或托珠单抗治疗重症 COVID-19 肺炎和中度炎症过度患者。一项回顾性队列研究。
Intern Emerg Med. 2021 Jun;16(4):843-852. doi: 10.1007/s11739-020-02600-z. Epub 2021 Jan 5.
7
Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019.静脉注射阿那白滞素治疗巨噬细胞活化综合征可能为治疗2019冠状病毒病细胞因子风暴提供经验教训。
ACR Open Rheumatol. 2020 May;2(5):283-285. doi: 10.1002/acr2.11140. Epub 2020 May 10.

[Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection].

作者信息

Figuero-Pérez Luis, Olivares-Hernández Alejandro, Escala-Cornejo Roberto A, Cruz-Hernández Juan J

机构信息

Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca, Salamanca, España.

Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España.

出版信息

Reumatol Clin. 2023 Feb;19(2):121. doi: 10.1016/j.reuma.2022.02.003. Epub 2022 Mar 14.

DOI:10.1016/j.reuma.2022.02.003
PMID:35308807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8919784/
Abstract
摘要